MedTech News - by Andrew Celentano
Diabeloop wins FDA nod for new automated insulin delivery algorithm
Diabeloop announced today that its DBLG2 algorithm for automated insulin delivery has received FDA 510(k) clearanc
Cytokinetics Wins FDA Approval, Clearing Way to Challenge BMS in Heart Disease Market
Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos.
Abbott earns FDA approval for Volt PFA system for AFib
Abbott (NYSE: ABT)+
announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with AFib.
Scientists build virtual tissue tools to map how cells talk in disease
Scientists at Duke-NUS Medical School have developed two powerful computational tools that could transform how researchers study the “conversations” between cells inside the body. The tools, called sCCIgen and QuadST, help scientists understand both where cells are located in tissues and how they communicate through genetic activity and chemical signals.
Ultrasound paired with vibrating nanoparticles softens tumor tissue, improving drug delivery
Cancer is one of the leading causes of death in the U.S., second only to heart disease. But a new cancer treatment method from CU Boulder researchers uses sound waves to soften tumors and could be a potent tool against the disease.
A urine-based biological aging clock: Machine learning and microRNA offer accurate prediction
Craif Inc. in Nagoya, Japan, working with Nagoya University’s Institute of Innovation for Future Society, has developed a urine-based biological aging clock. In validation of the method, predicted ages came within 4.4 years of chronological age on average.
Prostate cancer cells use unique metabolic pathway to thrive in bone tissue
A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in bone tissue, offering a potential new treatment target for patients with advanced disease.
Cancer’s hidden ‘safety switch’: Silencing TAK1 gene could boost immunotherapy performance
Australian researchers have discovered that the TAK1 gene helps cancer cells survive attack from the immune system, revealing a mechanism that may limit the effectiveness of immunotherapy treatments.